Dr Declan Doherty PhD has over 16 years of experience working in both academic and industrial research laboratories. He has worked at Ulster University, Queens University Belfast, Fusion Antibodies PLC and Almac Diagnostics Ltd. Since November 2022, he has held the position of Senior Scientist at CV6 Therapeutics (NI) Ltd where he is currently investigating mechanisms by which DNA damage can stimulate innate immune signalling in cancer cells.
Declans extensive research experience spans a variety of fields including oncology, immunology, cell biology and stem cells. In 2019, he gained recognition for his pioneering work on protein phosphatase 2A (PP2A), which was published in one of the leading journals in the field of respiratory science.
Declan was awarded a BSc (Hons) in Biomedical Science with a Diploma in Industrial Studies in 2003, a Masters of Research (MRes) in 2004, and a PhD in Biomedical Science in 2008 from the Ulster University. Declan also holds a teaching qualification from Queens University Belfast and became an Associate Fellow of the Higher Education Academy (AFHEA) in 2018.